Characteristics and outcomes of patients with COVID-19 at high-risk of disease progression receiving sotrovimab, oral antivirals or no treatment in England

Vishal Patel, Marcus J. Yarwood, Bethany Levick, Daniel C. Gibbons, Myriam Drysdale, William Kerr, Jonathan D. Watkins, Sophie Young, Benjamin F. Pierce, Emily J. Lloyd, Helen J. Birch, Tahereh Kamalati, Stephen J. Brett
doi: https://doi.org/10.1101/2022.11.28.22282808

Data Availability

The Discover-NOW data that support the findings of this study are available from Imperial College Health Partners via approval from the Discover Data Access Group (DRAG) under certain restrictions.

Back to top
Posted November 29, 2022.
Download PDF

Supplementary Material

Data/Code
Email
Characteristics and outcomes of patients with COVID-19 at high-risk of disease progression receiving sotrovimab, oral antivirals or no treatment in England
Vishal Patel, Marcus J. Yarwood, Bethany Levick, Daniel C. Gibbons, Myriam Drysdale, William Kerr, Jonathan D. Watkins, Sophie Young, Benjamin F. Pierce, Emily J. Lloyd, Helen J. Birch, Tahereh Kamalati, Stephen J. Brett
medRxiv 2022.11.28.22282808; doi: https://doi.org/10.1101/2022.11.28.22282808
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area